接受外周动脉疾病干预的医疗保险患者五年生存率:关联登记与索赔数据的回顾性队列分析
基于美国286个中心VQI登记与Medicare索赔关联数据,回顾性分析2010年1月1日至2021年5月31日间因间歇性跛行(IC)和慢性肢体威胁性缺血(CLTI)行外周血管介入(PVI)、腹股沟下搭桥(IIB)和腹股沟上搭桥(SIB)患者的五年生存率。结果显示IC和CLTI患者五年死亡率均较高,多变量分析确定终末期肾病、CLTI、充血性心力衰竭等与死亡率增加独立相关。
要点
- PVI后IC和CLTI的五年死亡率分别为37.2%和71.1%。
- IIB后IC和CLTI的五年死亡率分别为37.8%和60%。
- SIB后IC和CLTI的五年死亡率分别为33.8%和53.8%。
核心结论
- 接受外周动脉疾病干预的Medicare患者长期生存率差:约三分之二CLTI患者和超过三分之一IC患者在五年时已死亡。
- 作者认为,对于高死亡风险的IC患者应避免干预;对于生存可能性降低的CLTI患者,干预的耐久性可能不如侵入性重要。
- 术前应始终进行内科优化。
研究设计与样本
- 回顾性队列分析,查询VQI登记2010年1月1日至2021年5月31日期间286个美国中心因IC和CLTI行PVI、IIB和SIB的病例,并与Medicare保险索赔关联获取五年生存数据。
- 共纳入31 457例PVI(IC 44.7%,CLTI 55.3%)、7 978例IIB(IC 26.9%,CLTI 73.1%)和2 149例SIB(IC 50.1%,CLTI 49.9%)。
主要发现
- PVI、IIB和SIB队列平均年龄分别为75、73和72岁。
- PVI后IC和CLTI的五年死亡率分别为37.2%和71.1%;IIB后分别为37.8%和60%;SIB后分别为33.8%和53.8%。
- 多变量分析显示,在所有手术中,终末期肾病、CLTI、充血性心力衰竭、贫血、慢性阻塞性肺疾病和既往截肢与死亡率增加独立相关。
- 入院前居家生活和术前阿司匹林使用与死亡率降低独立相关。
临床怎么用
- 作者认为,对于高死亡风险的IC患者应避免干预。
- 作者认为,对于生存可能性降低的CLTI患者,干预的耐久性可能不如侵入性重要。
- 作者建议术前始终进行内科优化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To justify the up front risks of offering elective interventions for intermittent claudication (IC), patients should have reasonable life expectancy to derive durable clinical benefits. Open surgery for chronic limb threatening ischaemia (CLTI) is maximally beneficial in patients surviving ≥ 2 years. The aim was to assess long term survival after IC and CLTI interventions. METHODS: In a retrospective cohort analysis, the Vascular Quality Initiative (VQI) registry from 1 January 2010 to 31 May 2021 was queried for peripheral vascular intervention (PVI), infra-inguinal bypasses (IIB), and supra-inguinal bypasses (SIB) for IC and CLTI across 286 US centres. VQI linkage to Medicare insurance claims provided five year survival data. Multivariable analysis identified factors associated with five year mortality. RESULTS: There were 31 457 PVIs (44.7% IC, 55.3% CLTI), 7 978 IIBs (26.9% IC, 73.1% CLTI), and 2 149 SIBs (50.1% IC, 49.9% CLTI) recorded in the VQI. Among the PVI, IIB, and SIB cohorts, average ages were 75, 73, and 72 years, respectively. Respective five year mortality after PVI for IC and CLTI was 37.2% and 71.1%; after IIB for IC and CLTI it was 37.8% and 60%; and after SIB for IC and CLTI it was 33.8% and 53.8%. On multivariable analysis, across all procedures, end stage renal disease, CLTI, congestive heart failure, anaemia, chronic obstructive pulmonary disease, and prior amputation were independently associated with increased mortality. Pre-admission home living and pre-operative aspirin use were independently associated with decreased mortality. CONCLUSION: Long term survival in Medicare patients undergoing interventions in VQI centres for peripheral arterial disease is poor. Two thirds of CLTI patients and over one third of IC patients were not alive at five years. Intervening for IC in patients with high mortality risk should be avoided. For CLTI patients identified with decreased survival likelihood, intervention durability may be less important than invasiveness. Pre-operative medical optimisation should always be undertaken.
引用
- Levin SR, Farber A, Goodney PP, et al. Five Year Survival in Medicare Patients Undergoing Interventions for Peripheral Arterial Disease: a Retrospective Cohort Analysis of Linked Registry Claims Data. Eur J Vasc Endovasc Surg. 2023. PMID: 37543356. doi:10.1016/j.ejvs.2023.07.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。